Patients with confirmed pathological diagnosis of aggressive PTCL
Age 18-65 years old
Achieving CR or PR after first-line therapy
You may not be if
Subtypes with a more indolent course, including precursor T/natural killer neoplasms, T-cell large granular lymphocytic leukemia, mycosis fungoides other than transformed mycosis fungoides, Sézary syndrome, and primary cutaneous CD30-positive disorders.
